EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Pulmonary Delivery of TCR Bispecific Proteins via Mesenchymal Stem Cells Facilitates Efficient Clearance of Lung Cancers

Teng Wei, Wen Cao, Qiangnu Zhang, E Wu, Qineng Li, Lili Ren iD

Cancer Science · 2025

DOI: 10.1111/cas.70192 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Teng Wei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cytotherapy Laboratory, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern Un…. Hauptthemen laut MEDLINE: Lung Neoplasms, Mesenchymal Stem Cells, Receptors, Antigen, T-Cell, Antibodies, Bispecific. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shenzhen People's Hospital Physician Scientist Training "Five Three Program, National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T‐cell receptor (TCR) bispecific proteins represent a pioneering therapeutic modality that harnesses the diverse target recognition capabilities inherent to TCRs while preserving the beneficial characteristics associated with protein therapeutics. However, investigations into TCR bispecific proteins, particularly within the context of lung diseases, remain limited. This study aims to elucidate their potential for the treatment of lung cancer. We employed a humanized murine model to evaluate the efficacy of TCR bispecific proteins in eradicating lung tumors in vivo. Cytotoxic activity was assessed against various lung cancer cell lines, and statistical tests were used to analyze the data. To address concerns regarding toxic side effects from systemic administration, mesenchymal stem cells (MSCs) were explored as vehicles for the targeted delivery of TCR bispecific proteins. Our findings demonstrate that TCR bispecific proteins exhibit substantial cytotoxic activity against a variety of lung cancer cell lines. MSCs, with optimal pulmonary targeting properties, were shown to persist within the lungs for over 7 days. By employing MSCs to locally secrete TCR bispecific proteins, we achieved therapeutic effects comparable to systemic administration without manifestations of immune overactivation in murine subjects. Additionally, we evaluated various cytokine combinations and discovered that the combination of IL‐7, IL‐21, and TCR bispecific proteins significantly augmented their capacity to eliminate antigen‐negative cells in a heterogeneous tumor model. Collectively, our findings suggest that the combinatorial therapy of TCR bispecific proteins and MSCs holds considerable promise for clinical application in the treatment of lung cancer, potentially enhancing therapeutic efficacy while minimizing adverse effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsMesenchymal Stem CellsReceptors, Antigen, T-CellAntibodies, BispecificAnimalsHumansMiceCell Line, TumorFemaleXenograft Model Antitumor AssaysLung

Stichwörter der Autor:innen

TCR bispecific proteinslung cancermesenchymal stem cells

Substanzen

Receptors, Antigen, T-CellAntibodies, Bispecific

Autor:innen und Institutionen

  • Cytotherapy Laboratory, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China; Schoo…
  • Biomedicine Research Center, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
  • Department of Respiratory Medicine, The Second Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi, China.

ORCID-Profile: Lili Ren

Förderung

  • Shenzhen People's Hospital Physician Scientist Training "Five Three Program
  • National Natural Science Foundation of China
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Shenzhen Science and Technology Program

Zitieren

APA

Wei, T., Cao, W., Zhang, Q., Wu, E., Li, Q., & Ren, L. (2025). Pulmonary Delivery of TCR Bispecific Proteins via Mesenchymal Stem Cells Facilitates Efficient Clearance of Lung Cancers. Cancer Science. https://doi.org/10.1111/cas.70192

Vancouver

Wei T, Cao W, Zhang Q, Wu E, Li Q, Ren L. Pulmonary Delivery of TCR Bispecific Proteins via Mesenchymal Stem Cells Facilitates Efficient Clearance of Lung Cancers. Cancer Science. 2025. doi:10.1111/cas.70192

BibTeX
@article{Wei2025,
  author = {Wei, Teng and Cao, Wen and Zhang, Qiangnu and Wu, E and Li, Qineng and Ren, Lili},
  title = {Pulmonary Delivery of TCR Bispecific Proteins via Mesenchymal Stem Cells Facilitates Efficient Clearance of Lung Cancers},
  journal = {Cancer Science},
  year = {2025},
  doi = {10.1111/cas.70192}
}
Kostenlos starten →